ERBB2 and gastric cancer: However, the GATSBY trial demonstrated no OS or PFS benefit with T-DM1 versus taxanes in HER2-positive advanced GC patients, likely attributed to HER2 heterogeneity within these tumors (Thuss-Patience et al., 2017).